$30 Million is the total value of ABG-WTT Global Life Science Capital Partners GP Ltd's 3 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CG ONCOLOGY INC | $28,902,367 | -28.1% | 915,501 | 0.0% | 96.44% | -0.4% | ||
| RAPID MICRO BIOSYSTEMS INC | $685,275 | -10.8% | 1,038,296 | 0.0% | 2.29% | +23.6% | ||
| LUNG | PULMONX CORP | $381,693 | -31.6% | 60,204 | 0.0% | 1.27% | -5.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PULMONX CORP | 15 | Q2 2024 | 49.0% |
| MEDAVAIL HOLDINGS INC | 12 | Q3 2023 | 92.0% |
| RAPID MICRO BIOSYSTEMS INC | 10 | Q2 2024 | 57.2% |
| CG ONCOLOGY INC | 2 | Q2 2024 | 96.8% |
| RAYZEBIO INC | 2 | Q4 2023 | 94.4% |
| MEDAVAIL HOLDINGS | 1 | Q4 2023 | 2.6% |
View ABG-WTT Global Life Science Capital Partners GP Ltd's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-21 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-03-15 |
| 13F-HR | 2023-02-14 |
View ABG-WTT Global Life Science Capital Partners GP Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.